Literature DB >> 11344274

Antiviral activities of the soluble extracellular domains of type I interferon receptors.

C S Han1, Y Chen, T Ezashi, R M Roberts.   

Abstract

Alternative splicing leads to the expression of multiple isoforms of the subunits (IFNAR1 and IFNAR2) of the type I IFN receptor. Here we describe two transcripts representing extracellular forms of ovine IFNAR1 and show that soluble extracellular forms of both IFNAR2 and IFNAR1, prepared in recombinant form in Escherichia coli, have antiviral (AV) activity in the absence of IFN. Exposure of Madin-Darby bovine kidney cells to the extracellular domain (R2E) of IFNAR2 at concentrations as low as 10 nM afforded complete protection against vesicular stomatitis virus and led to the rapid activation of the transcription factors ISGF3 and GAF. Although R2E can bind IFN (K(d) approximately 70 nM), activity was observed irrespective of whether or not ligand was present. R2E was inactive on mouse L929 cells but active on L929 cells expressing a membraneanchored, ovine/human chimeric IFNAR2 with an ovine extracellular domain. The data suggest that AV activity is conferred by the ability of soluble R2E to associate with the transfected IFNAR2 subunit rather than resident murine IFNAR1. Soluble extracellular forms of IFNAR1 have lower AV activity than R2E on Madin-Darby bovine kidney cells but are less species-specific and protect wild-type L929 cells as efficiently as the transfected cell line, presumably by interacting with one of the murine receptor subunits.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344274      PMCID: PMC33435          DOI: 10.1073/pnas.111139598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.

Authors:  R M Arduini; K L Strauch; L A Runkel; M M Carlson; X Hronowski; S F Foley; C N Young; W Cheng; P S Hochman; D P Baker
Journal:  Protein Sci       Date:  1999-09       Impact factor: 6.725

Review 2.  The type I interferon receptor: structure, function, and evolution of a family business.

Authors:  K E Mogensen; M Lewerenz; J Reboul; G Lutfalla; G Uzé
Journal:  J Interferon Cytokine Res       Date:  1999-10       Impact factor: 2.607

3.  The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential.

Authors:  A P Alexenko; A D Ealy; R M Roberts
Journal:  J Interferon Cytokine Res       Date:  1999-12       Impact factor: 2.607

4.  Structure of an ovine interferon receptor and its expression in endometrium.

Authors:  S Kaluz; P A Fisher; M Kaluzova; E L Sheldrick; A P Flint
Journal:  J Mol Endocrinol       Date:  1996-12       Impact factor: 5.098

5.  Bovine interferon-tau stimulates the Janus kinase-signal transducer and activator of transcription pathway in bovine endometrial epithelial cells.

Authors:  M Binelli; P Subramaniam; T Diaz; G A Johnson; T R Hansen; L Badinga; W W Thatcher
Journal:  Biol Reprod       Date:  2001-02       Impact factor: 4.285

6.  The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties.

Authors:  M P Hardy; C M Owczarek; S Trajanovska; X Liu; I Kola; P J Hertzog
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

7.  Creation of phosphorylation sites in proteins: construction of a phosphorylatable human interferon alpha.

Authors:  B L Li; J A Langer; B Schwartz; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

8.  In vivo kinetics of a covalent growth hormone-binding protein complex.

Authors:  G Baumann; M A Shaw; T A Buchanan
Journal:  Metabolism       Date:  1989-04       Impact factor: 8.694

9.  Dimerization of the interferon type I receptor IFNaR2-2 is sufficient for induction of interferon effector genes but not for full antiviral activity.

Authors:  E Pattyn; X Van Ostade; L Schauvliege; A Verhee; M Kalai; J Vandekerckhove; J Tavernier
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

10.  Expression and biological activity of two recombinant polypeptides related to subunit 1 of the interferon-alpha receptor.

Authors:  S Yoon; R D Hirata; N Y Nguyen; R Curi; M Russo; M H Hirata
Journal:  Braz J Med Biol Res       Date:  2000-07       Impact factor: 2.590

View more
  6 in total

1.  IL12Rβ1ΔTM is a secreted product of il12rb1 that promotes control of extrapulmonary tuberculosis.

Authors:  Aurelie A Ray; Jeffrey J Fountain; Halli E Miller; Andrea M Cooper; Richard T Robinson
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

Review 2.  New roles for the major human 3'-5' exonuclease TREX1 in human disease.

Authors:  David Kavanagh; Dirk Spitzer; Parul H Kothari; Aisha Shaikh; M Kathryn Liszewski; Anna Richards; John P Atkinson
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

3.  Peripheral type I interferon receptor correlated with oxidative stress in chronic hepatitis B virus infection.

Authors:  Jing Zhao; Yu-Chen Fan; Feng-Kai Sun; Ze-Hua Zhao; Li-Yuan Wang; Lei-Hua Hu; Yan-Ping Yin; Tao Li; Shuai Gao; Kai Wang
Journal:  J Interferon Cytokine Res       Date:  2013-05-10       Impact factor: 2.607

4.  The differential antiviral activities of chicken interferon α (ChIFN-α) and ChIFN-β are related to distinct interferon-stimulated gene expression.

Authors:  Hongren Qu; Limin Yang; Shanshan Meng; Lei Xu; Yuhai Bi; Xiaojuan Jia; Jing Li; Lei Sun; Wenjun Liu
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

5.  The skin transcriptome in hidradenitis suppurativa uncovers an antimicrobial and sweat gland gene signature which has distinct overlap with wounded skin.

Authors:  Margaret Coates; Paula Mariottoni; David L Corcoran; Hélène Fradin Kirshner; Tarannum Jaleel; David A Brown; Stephen R Brooks; John Murray; Maria I Morasso; Amanda S MacLeod
Journal:  PLoS One       Date:  2019-05-06       Impact factor: 3.240

6.  Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß Mediation.

Authors:  Isaac Hurtado-Guerrero; Bruno Hernáez; María J Pinto-Medel; Esther Calonge; José L Rodriguez-Bada; Patricia Urbaneja; Ana Alonso; Natalia Mena-Vázquez; Pablo Aliaga; Shohreh Issazadeh-Navikas; José Pavia; Laura Leyva; José Alcamí; Antonio Alcamí; Óscar Fernández; Begoña Oliver-Martos
Journal:  J Clin Med       Date:  2020-03-31       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.